ABSTRACT
Personalized medicine aims to ensure customized healthcare, which proposes disease prevention, medical decision, and tailored therapy for each condition/patient, taking information from integrative studies. However, omics integration is in its infancy. Single-omics analyses on cancer patient samples have provided valuable data available to the scientific community, mostly in the field of genomics, although matched clinical annotation is limited. A great step forward in precision medicine could derive from a pan-cancer analysis of multiple omics profiles on a genome-wide scale, in order to understand the shared patterns across cancer types and identify shared actionable targets at a multilayer level. It therefore appears evident that the integration of omics data represents a powerful tool to allow clinical translation of this integrated dissection of cancer biology. Metabolomics have important potential in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamic marker of drug effect for therapeutic evaluation.
